Akari Therapeutics (AKTX) Non-Current Assets (2012 - 2026)
Akari Therapeutics recorded quarterly Non-Current Assets of $30.3 million in Q1 2026, down 28.59% quarter-over-quarter from $42.4 million in Q4 2025, and down 36.36% year-over-year from $47.6 million in Q1 2025.
Akari Therapeutics' Non-Current Assets history runs 14 years deep, the most recent figure standing at $30.3 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 36.36% year-over-year to $30.3 million; the TTM figure through Mar 2026 stood at $162.8 million (up 70.94% YoY), while the FY2025 annual figure was $42.4 million, down 10.88% from the prior year.
- Non-Current Assets came in at $30.3 million for Q1 2026 at Akari Therapeutics, down from $42.4 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $47.6 million in Q4 2024 to a low of $14000.0 in Q4 2023.
- A 5-year average of $23.5 million and a median of $30.3 million in 2026 frame the typical range for Non-Current Assets.
- Across the five-year window, Non-Current Assets tumbled 100.0% in 2022 and surged 339971.43% in 2024, its largest moves.
- Akari Therapeutics' Non-Current Assets stood at $17000.0 in 2022, then fell by 17.65% to $14000.0 in 2023, then soared by 339971.43% to $47.6 million in 2024, then fell by 10.88% to $42.4 million in 2025, then declined by 28.59% to $30.3 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $30.3 million, $42.4 million, and $42.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | 285.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.30 Mn |
| Dec 31, 2025 | 42.43 Mn |
| Sep 30, 2025 | 42.43 Mn |
| Jun 30, 2025 | 47.61 Mn |
| Mar 31, 2025 | 47.61 Mn |
| Dec 31, 2024 | 47.61 Mn |
| Dec 31, 2023 | 14,000.00 |
| Jun 30, 2023 | 15,779.00 |
| Dec 31, 2022 | 17,000.00 |
| Jun 30, 2022 | 18,844.00 |
| Mar 31, 2022 | 21,335.00 |
| Dec 31, 2021 | 38.47 Bn |
| Sep 30, 2021 | 23,927.00 |
| Jun 30, 2021 | 25,546.00 |
| Mar 31, 2021 | 26,460.00 |
| Dec 31, 2020 | 27.00 |
| Sep 30, 2020 | 26,674.00 |
| Jun 30, 2020 | 26,489.00 |
| Mar 31, 2020 | 29,662.00 |
| Dec 31, 2019 | 35.00 |
| Sep 30, 2019 | 37,535.00 |
| Jun 30, 2019 | 60,485.00 |
| Mar 31, 2019 | 196,625.00 |
| Dec 31, 2018 | 40.72 Bn |
| Sep 30, 2018 | 586,414.00 |
| Jun 30, 2018 | 596,273.00 |
| Mar 31, 2018 | 229,236.00 |
| Dec 31, 2017 | 61.89 Bn |
| Sep 30, 2017 | 233,059.00 |
| Jun 30, 2017 | 248,242.00 |
| Mar 31, 2017 | 234,991.00 |
| Dec 31, 2016 | 70.08 Bn |
| Sep 30, 2016 | 246,270.00 |
| Jun 30, 2016 | 259,120.00 |
| Mar 31, 2016 | 265,855.00 |
| Dec 31, 2015 | 93.33 Bn |
| Sep 30, 2015 | 235,110.00 |
| Jun 30, 2015 | 40,000.00 |
| Mar 31, 2015 | 44,000.00 |
| Dec 31, 2014 | 59,417.00 |
| Dec 31, 2012 | 2,000.00 |